Clinical trials: Relapsed and Refractory Multiple Myeloma (RRMM)
Plasma Cell Myeloma
First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma
Primary Objectives: Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended…
- Trial name
- NCT04000282
- Testing
- SAR442085
- Where
- 12 sites in United States, Czechia and 4 more
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Sanofi